ICER to evaluate buprenorphines for opioid disorder

The Institute for Clinical and Economic Review said it will develop a report that will compare the clinical effectiveness of three buprenorphine products to commonly used drugs for medication-assisted treatment of opioid use disorder.

In its review, ICER will evaluate approved buprenorphine products, including the once-monthly injectable Sublocade and the implant Probuphine, as well as extended-release injection CAM2038, which received a complete response letter from FDA in January. The institute said it will compare the products to drugs such as methadone, Suboxone buprenorphine/naltrexone sublingual film and injectable Vivitrol naltrexone...